Navigation Links
New and improved gluten-free foods developed for patients with celiac disease
Date:5/5/2010

A wide range of gluten free cereals have been studies in detail as part of the HEALTHGRAIN project of the European Union, and their impact on product quality has been assessed. Enzyme technology, bioprocessing as well as high-pressure processing technology have been successfully applied to improve the quality, safety and nutritional attributes of gluten free cereal products.

In genetically susceptible individuals, the ingestion of gluten and related proteins triggers an immunemediated enteropathy known as Coeliac Disease (CD). Recent epidemiological studies have shown that 1 in 100 people worldwide suffer from CD. Such a rate establishes CD as one of the most common food intolerances. Coeliac patients eating wheat or related proteins such as hordeins (barley) or secalins (rye) undergo an immunological response, localized in the small intestine, which destroys mature absorptive epithelial cells on the surface of the small intestine.

Currently, the only way that CD can be treated is the total lifelong avoidance of gluten ingestion. Therefore, CD suffers have to follow a very strict diet and avoid any products which contain wheat, rye or barley. Some authors also include oats. Avoidance of these cereals leads to a recovery from the disease and significant improvement of the intestinal mucosa and its absorptive functions. Coeliac patients are not in position to eat some of the most common foods such as bread, pizzas, biscuits or drink beer.

Due to the unique properties of gluten, it is a big challenge for food scientists to produce good quality gluten free products. The majority of products currently on the market are in general of very poor quality. Therefore part of the HEALTHGRAIN project focused on the development of nutritious and tasty gluten free breads.

The areas covered during the project were a detailed characterisation of gluten free cereals and the assessment of these cereals as potential ingredients for gluten free breads. The characterizations ranged from a detailed chemical characterisation to rheological evaluation of the resulting doughs, structural properties of the doughs and breads using advanced microscopic methods as well as pilotscale baking trials and sensory evaluation. Novel methods to improve the quality of gluten free cereal products were also covered; one example being the use of specially selected Lactic acid bacteria with properties such as antifungal activity, exopolysaccharide production and enzyme production. The use of specifically selected Lactic acid bacteria can significantly improve the quality and shelf-life of gluten free breads.

One of the major problems associated with gluten free products is their texture. Part of the project was therefore to investigate the influence of a range of enzymes such as transglutaminase, glucose oxidase and protease on wide range of gluten free cereals. It was shown that enzymes can play an important role in improving the structure of gluten free bread, but the enzymes showed different interactions with the various gluten free flours.

Novel processing such as high pressure processing was also introduced as a means to create ingredients for gluten free cereal products. The impact of HP was investigated on the major polymers found in gluten free flours, such as starch and protein was also performed. The results revealed that starch gelatinisation and protein network formation at pressures ≥ 350 MPa was obtained while a weakening of protein structures was observed at lower pressures. Addition of HP-treated gluten free batters to bread resulted in improved volume and decreased staling at 200 MPa, while higher pressures did not improve oat bread quality. The work was conducted by the research team of Professor Elke Arendt, University College Cork, Ireland. Part of the Nutritional analysis of the gluten free flours was conducted by the team of Professor Jan Delcour, KU Leuven, Belgium.


'/>"/>

Contact: Elke Arendt
e.arendt@ucc.ie
35-321-490-2064
VTT Technical Research Centre of Finland
Source:Eurekalert

Related biology news :

1. Primary Energy Reports Improved First Quarter Results
2. Drinking 100 percent fruit juice is associated with improved diet quality in children
3. BIO-key(R) International Biometric Accuracy Improved by More Than 23% as Reported in Recent NIST Testing
4. Improved near-real-time tracking of 2010 El Niño reveals marine life reductions
5. Air Force Center of Excellence awarded in nanostructures and improved cognition
6. Improved adhesive for products like transparent tape could benefit biofuels economy
7. Improved Endo Capsule Software enhances diagnostic experience
8. Improved diet and exercise alone unlikely to cure obstructive sleep apnea in obese patients
9. New portal for plant genomics will support research into improved crops
10. Improved air quality during Beijing Olympics could inform pollution-curbing policies
11. Newly discovered gene fusion may lead to improved prostate cancer diagnosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... BARCELONA , Spanien, 27. Februar 2017 /PRNewswire/ ... durch Iris-Scan, wird seine erstklassige biometrische Lösung ... Snapdragon™ 835 mit X16 LTE auf dem ... 2. März) am Qualcomm-Stand in Halle 3, ... 835-Prozessor beinhaltet die Sicherheitsplattform Qualcomm Haven™ – ...
(Date:2/21/2017)... and PORTLAND, Ore. , Feb. 22, ... Avamere Family of Companies (Avamere Health Services, Infinity Rehab, ... six-month research study that will apply the power of ... senior living and health centers. By analyzing data streaming ... gain insights into physical and environmental conditions, and obtain ...
(Date:2/13/2017)... 13, 2017 Former 9/11 Commission border counsel ... Janice Kephart of Identity Strategy Partners, LLP, ... Trump,s "Executive Order: Protecting the Nation From Foreign ... "As President Trump,s ,Travel Ban, Executive Order ... essentially banned the travel ban, it is important that ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... March 23, 2017  Northwest Biotherapeutics (OTCQB: NWBO) ... immune therapies for solid tumor cancers, today announced ... financing it announced last Friday, March 17, 2017. ... institutional investors securities totaling 28,843,692 shares, comprised of ... 10,000,000 shares of Class C Warrants pre-funded at ...
(Date:3/23/2017)...  BioPharmX Corporation (NYSE MKT: BPMX), a specialty ... today reported financial results for the quarter and ... an update on the company,s clinical development efforts ... are pleased to report that last year was ... Anja Krammer. "We achieved key clinical milestones and ...
(Date:3/23/2017)... NetworkNewsWire Editorial Coverage  ... Cancer remains one of ... health care systems, in terms of costs and resources. However, ... the development of innovative and efficient therapies that demonstrate higher ... types of cancer treatments, a growing number of patients receiving ...
(Date:3/23/2017)... , March 23, 2017 ... at four equities in the Biotech industry: Sangamo Therapeutics ... Biologics Inc. (NYSE MKT: SYN), and Regulus Therapeutics Inc. ... st , 2017, Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology ... downloading their free report at: ...
Breaking Biology Technology: